Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zeping Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an 71…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Histone Deacetylase 6, Histone Deacetylase Inhibitors. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Xi'an Municipal Bureau of Science and Technology, Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Basic Research Program of Shaanxi Province.
Abstract (Originalsprache)
Histone deacetylase 6 (HDAC6) is a pivotal epigenetic regulator and is involved in the tumorigenesis and progression. Our previous study revealed that HDAC6 is overactivated in hepatocellular carcinoma (HCC), and identified SelSA as a novel HDAC6 inhibitor (HDAC6i) for HCC therapy. In this work, we optimized this inhibitor and discovered 14a as a novel HDAC6i with better efficacy against HDAC6 and HepG2 cells than SelSA through structure-activity relationship (SAR) studies. The flow cytometry indicated that 14a markedly induced apoptosis and cell cycle arrest at the S phase in HepG2 cells. Mechanistic studies demonstrated that 14a effectively downregulated the levels of HDAC6 and the phosphorylation of ERK1/2, and attenuated the migration, invasion, and clonogenicity of HepG2 cells. More crucially, 14a possessed more potency to suppress tumor growth in HepG2 xenograft models compared to SelSA, without obvious toxicity. In summary, 14a represents a novel HDAC6i with anti-HCC effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an 710126, Shaanxi, China.
- Department of Medical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi, China.
- Institute of Medical Engineering, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.
ORCID-Profile: Fu Wang
Förderung
- Xi'an Municipal Bureau of Science and Technology
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Basic Research Program of Shaanxi Province
- Xidian University
- Guangzhou Municipal Science and Technology Project
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Yang, Z., Wu, Y., Kong, F., Zhang, Y., Jia, L., Tang, C., & Wang, F. (2026). Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02763
Vancouver
Yang Z, Wu Y, Kong F, Zhang Y, Jia L, Tang C, et al. Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02763
BibTeX
@article{Yang2026,
author = {Yang, Zeping and Wu, Yuanqing and Kong, Feizhi and Zhang, Yue and Jia, Lijun and Tang, Chu and Wang, Fu},
title = {Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02763}
}
EUVIMED